HAO1 and primary hyperoxaluria type 1: In recent years, the RNA interference (RNAi) therapy lumasiran has been shown to decrease urinary oxalate (Uox) and Pox levels, by reducing glycolate oxidase (GO; encoded by the HAO1 gene) synthesis in patients living with PH1 [16–18].